Business Wire

Through the Simultaneous Merger of Six Companies, Ronin Helps Create the Only End-to-End Provider of Craft Brewery & Beverage Equipment in North America

20.4.2023 14:30:00 EEST | Business Wire | Press release

Share

Operationally-focused buyout group, Ronin Equity Partners, has created Lotus Beverage Alliance through the simultaneous merger of six companies. The new group has 75 years of combined experience with locations in Lincoln, Nebraska, Ypsilanti, Michigan, Denver, Colorado, Portland, Oregon, and Hopewell Junction, New York. Lotus is a partnership of Alpha Brewing Operations, GW Kent, Twin Monkeys, Stout Tanks and Kettles, Brewmation and Automated Extractions.

Lotus’ more than 1,500 products and services - some patented and many customized - cover canning systems, automation and control systems, turn-key brewhouse construction, packaging, thermal processes, tanks and sanitation equipment. With a recurring spare parts business across all product lines, Lotus is the only company in North America to cover every step of craft brewery and beverage production, from raw ingredient supply to canning and other forms of packaging. In another first, Lotus has introduced a proprietary financing program that offers customers affordable financing options for all the company’s product lines. To provide, clients with maximum flexibility, credit approvals typically take less than 24 hours.

Ronin owns the majority of Lotus, and together, the six companies have a combined value of $100 million. Founders and management hold a significant double-digit ownership percentage, and Ronin has implemented an equity incentive program throughout the organization, extending to even the most junior employees. Research has shown that broad-based employee ownership programs improve worker retention, reduce income disparity, and result in higher margins, as well as improved growth and operating efficiencies across various aspects of a business. Ronin collaborated with Ownership Works in this employee ownership program’s creation.

“As the industry’s only one-stop shop, Lotus has everything that craft beverage creators need to produce the products they love, for the people who love them,” says John Ansbro, Lotus’ newly appointed CEO. “Our ownership structure makes us even more responsive to clients.”

Ansbro, an industry veteran with over 30 years of experience in equipment manufacturing (holding senior executive positions at Alfa Laval, Johnson Controls and the GEA Group) will be joined by Ronin Managing Partner and co-founder Jesse Yao, who will embed as Lotus’ CFO. Ronin Vice-President Jack Burke and Associate Elliott Rogasik are also taking senior executive positions. The board includes six Ronin operating advisors with experience running global operations at some of the world’s largest (or most celebrated) beer, food and beverage manufacturers, including SABMiller, AB InBev, Harpoon Brewery, KraftHeinz, Naked Juice and Ocean Spray).

“We are thrilled at the prospect of uniting a fragmented craft beverage supply landscape through a remarkable alliance of industry partners.” says Yao. “By embedding Ronin executives in the back office, our corporate partners can concentrate more fully on expanding their product range and increasing sales.” Managers and founders from the six merged companies form the bulk of senior management at Lotus.

On a combined basis, sales for the merged group rose 29 percent over three years to $65 million in 2022 while earnings before interest, tax, depreciation and amortization increased 39 percent. Rapidly growing international sales in Europe and Asia where high-quality, smaller-batch craft beer production is just taking off, accounts for some 7 percent of combined group sales, increasing from virtually nothing in 2019.

Beyond the purchase price, Ronin has reserved nearly $35 million in pre-arranged financing to fund acquisitions for Lotus in the Americas, Europe and Asia. Ronin and Lotus have identified more than 50 potential acquisitions and are in active discussions with nine of those companies.

In addition to craft beer, Lotus’ products and services are equally suited to other fast growing beverage markets including kombucha, cold brew coffee, hard seltzer, ready-to-drink cocktails, premium wines and ciders, and cannabis-infused drinks. These products currently account for some 26 percent of sales.

The six acquisitions forming Lotus were financed using Ronin’s balance sheet, with investments from a range of limited partners, including Nicola Wealth and Fiera Comox.

Since the first quarter of 2021, when it began investing, Ronin has deployed over $350 million including reserves for follow-on portfolio investment. The capital was committed to five platform investments, comprising a total of 21 companies. Since deal close - i.e. within two years - annualized earnings before interest, taxes, depreciation and amortization at Ronin’s first four platform companies have risen 30 percent to $104 million, while annualized revenues are up 23 percent to $484 million.

Triago Americas Inc., acted as sole placement agent on all of Ronin’s platform investments, including the Lotus transaction. Katten Muchin Rosenman acted as Ronin’s legal advisor on Lotus; buyside M&A advisors were KeyBanc and Harvey & Company. Debt was provided by Webster Bank as Lead Left Bookrunner & Administrative Agent and by Texas Capital Bank, BHI and Stifel Bank as Joint Lead Arrangers.

About Ronin Equity Partners

Based in New York City, Ronin Equity Partners represents a new type of investment firm, powered by an operationally-focused value creation strategy. Ronin makes control equity investments exclusively in the Industrial and Consumer sectors, where the team has prior expertise. The group buys strong businesses with high demonstrated cash flows, where Ronin’s operating playbook adds value. The Ronin team embeds into each company as interim senior executives to build a robust back-office infrastructure capable of scaling the business for growth and seamlessly integrating acquisitions. This partnership empowers management to focus entirely on growing the business without being burdened by back-office operations. The firm was founded in 2019 by Managing Partners David Feierstein and Jesse Yao alongside other former senior executives from Kraft Heinz, NCR, and Diversey. The firm is supported by some 75 operating advisors in the consumer and industrials sectors. www.roninequitypartners.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

David Lanchner, dlanchner@yahoo.com, +33 (0)6 3343-5076

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye